BAUMGARTNER, T., M. CARRENO, R. ROCAMORA, F. BISULLI, A. BONI, Milan BRÁZDIL, Ondřej HORÁK, D. CRAIU, C. PEREIRA, R. GUERRINI, V. SAN ANTONIO-ARCE, A. SCHULZE-BONHAGE, S. M. ZUBERI, T. HALLBOOK, R. KALVIAINEN, L. LAGAE, S. NGUYEN, S. QUINTAS, A. FRANCO, J. H. CROSS, M. WALKER, A. ARZIMANOGLOU, S. RHEIMS, T. GRANATA, L. CANAFOGLIA, C. J. LANDMARK, A. SEN, R. RATTIHALLI, R. NABBOUT, E. TARTARA, M. SANTOS, R. RANGEL, P. KRSEK, P. MARUSIC, N. SPECCHIO, K. P. J. BRAUN, P. SMEYERS, V. VILLANUEVA, K. KOTULSKA a R. SURGES. A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies. Epilepsia Open. HOBOKEN: WILEY, 2021, roč. 6, č. 1, s. 160-170. ISSN 2470-9239. Dostupné z: https://dx.doi.org/10.1002/epi4.12459.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název A survey of the European Reference Network EpiCARE on clinical practice for selected rare epilepsies
Autoři BAUMGARTNER, T., M. CARRENO, R. ROCAMORA, F. BISULLI, A. BONI, Milan BRÁZDIL (203 Česká republika, domácí), Ondřej HORÁK (203 Česká republika, domácí), D. CRAIU, C. PEREIRA, R. GUERRINI, V. SAN ANTONIO-ARCE, A. SCHULZE-BONHAGE, S. M. ZUBERI, T. HALLBOOK, R. KALVIAINEN, L. LAGAE, S. NGUYEN, S. QUINTAS, A. FRANCO, J. H. CROSS, M. WALKER, A. ARZIMANOGLOU, S. RHEIMS, T. GRANATA, L. CANAFOGLIA, C. J. LANDMARK, A. SEN, R. RATTIHALLI, R. NABBOUT, E. TARTARA, M. SANTOS, R. RANGEL, P. KRSEK, P. MARUSIC, N. SPECCHIO, K. P. J. BRAUN, P. SMEYERS, V. VILLANUEVA, K. KOTULSKA a R. SURGES (garant).
Vydání Epilepsia Open, HOBOKEN, WILEY, 2021, 2470-9239.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30210 Clinical neurology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 4.026
Kód RIV RIV/00216224:14110/21:00122123
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1002/epi4.12459
UT WoS 000648553600018
Klíčová slova anglicky autoimmune encephalitis; Dravet syndrome; orphan disease; progressive myoclonic epilepsy; targeted therapies; tuberous sclerosis complex
Štítky 14110127, 14110320, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Mgr. Tereza Miškechová, učo 341652. Změněno: 19. 8. 2021 09:02.
Anotace
ObjectiveClinical care of rare and complex epilepsies is challenging, because evidence-based treatment guidelines are scarce, the experience of many physicians is limited, and interdisciplinary treatment of comorbidities is required. The pathomechanisms of rare epilepsies are, however, increasingly understood, which potentially fosters novel targeted therapies. The objectives of our survey were to obtain an overview of the clinical practice in European tertiary epilepsy centers treating patients with 5 arbitrarily selected rare epilepsies and to get an estimate of potentially available patients for future studies. MethodsMembers of the European Reference Network for rare and complex epilepsies (EpiCARE) were invited to participate in a web-based survey on clinical practice of patients with Dravet syndrome, tuberous sclerosis complex (TSC), autoimmune encephalitis, and progressive myoclonic epilepsies including Unverricht Lundborg and Unverricht-like diseases. A consensus-based questionnaire was generated for each disease. ResultsTwenty-six of 30 invited epilepsy centers participated. Cohorts were present in most responding centers for TSC (87%), Dravet syndrome (85%), and autoimmune encephalitis (71%). Patients with TSC and Dravet syndrome represented the largest cohorts in these centers. The antiseizure drug treatments were rather consistent across the centers especially with regard to Dravet syndrome, infantile spasms in TSC, and Unverricht Lundborg / Unverricht-like disease. Available, widely used targeted therapies included everolimus in TSC and immunosuppressive therapies in autoimmune encephalitis. Screening for comorbidities was routinely done, but specific treatment protocols were lacking in most centers. SignificanceThe survey summarizes the current clinical practice for selected rare epilepsies in tertiary European epilepsy centers and demonstrates consistency as well as heterogeneity in the treatment, underscoring the need for controlled trials and recommendations. The survey also provides estimates for potential participants of clinical trials recruited via EpiCARE, emphasizing the great potential of Reference Networks for future studies to evaluate new targeted therapies and to identify novel biomarkers.
VytisknoutZobrazeno: 30. 4. 2024 12:21